Mumbai-based Arch Pharmalabs announced the signing of a co-marketing agreement with Sibra Pharmaceuticals here for sale of anti-retro viral (ARV) drugs. Under the pact, Arch Pharmalabs will market the range of Sibra's ARVs exclusively both for Indian and global markets. In a press release, Ajit Kamath, chairman and managing director, said Arch Pharmalabs would actively seek more such agreements to expand its offerings across therapeutic segments.
Statistics
SUPPORT (183 Members) . GROW (7 Association). PROMOTE (Visitors from 14 Countries).
(Check The Site's Statistics)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment